Moreover, UA sensitizes CRC to standard therapies: it downregulates chemoresistance mechanisms (MDR1, BCRP, MRP transporters) via the FOXO3–FOXM1 pathway, thereby restoring 5-FU efficacy [21]. The gene discussed is FOXO3; the disease is colorectal carcinoma.